Inclusion Criteria:~1. Age ≥ 50~2. Fluent in English~3. Biomarker confirmed AD with CSF level of Abeta42
<600ng/mL~4. Able to ingest oral medications~5. Diagnosis of mild to moderate AD according to dementia criteria
outlined by McKhann et al.~6. Neuroimaging (MRI or CT) consistent with the diagnosis of AD within the past
year~7. MMSE between 17 and 24 (inclusive) at screening~8. Modified Hachinski score ≤ 4~9. QTc interval
350-460ms, inclusive~10. Caregiver/study partner to accompany participant to all visits and have direct contact
with the participant > 2 days/week~11. Written informed consent~12. Capability and willingness to comply with
all study criteria~13. Supervision available for study medication~14. Stable medical conditions for 3 months
prior to screening visit~15. Stable medications for 4 weeks prior to screening visit~16. Able to complete
baseline assessments~17. Minimum of 6 years of education, or work history sufficient to exclude mental
retardation~18. Stable use of cholinesterase inhibitors and memantine (U.S. FDA-approved medications for
patients with probable AD), vitamin E (up to 400 IU daily), estrogens, aspirin (81-300 mg daily), and
cholesterol-lowering agents for 3 months prior to screening is allowed.~19. Clinical laboratory values within
normal limits or, if abnormal, must be judged to be clinically insignificant by the investigator~
